# EDGAR Filing Document

**Accession Number:** 0001608730
**File Stem:** 0000105770-25-000074
**Filing Date:** 2025-8
**Character Count:** 9430
**Document Hash:** d9d4259d91ec4126a805c08d3b01e8db
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000105770-25-000074.hdr.sgml**: 20250812

**ACCESSION NUMBER**: 0000105770-25-000074

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250811

**FILED AS OF DATE**: 20250812

**DATE AS OF CHANGE**: 20250812

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** McMahon Robert W.
- **CENTRAL INDEX KEY:** 0001608730

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-08036
- **FILM NUMBER:** 251208474

**MAIL ADDRESS:**
- **STREET 1:** C/O AGILENT TECHNOLOGIES, INC.
- **STREET 2:** 5301 STEVENS CREEK BLVD.
- **CITY:** SANTA CLARA
- **STATE:** CA
- **ZIP:** 95051
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** WEST PHARMACEUTICAL SERVICES INC
- **CENTRAL INDEX KEY:** 0000105770
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 231210010
- **STATE OF INCORPORATION:** PA
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 530 HERMAN O. WEST DRIVE
- **CITY:** EXTON
- **STATE:** PA
- **ZIP:** 19341
- **BUSINESS PHONE:** 6105942900

**MAIL ADDRESS:**
- **STREET 1:** 530 HERMAN O. WEST DRIVE
- **CITY:** EXTON
- **STATE:** PA
- **ZIP:** 19341

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WEST CO INC
- **DATE OF NAME CHANGE:** 19990405

## Ex-24

```

LIMITED POWER OF ATTORNEY FOR

WEST PHARMACEUTICAL SERVICES, INC.

SECTION 16(a) FILINGS

Know all by these presents that the undersigned hereby constitutes and
appoints each of Luis Cantarero, Louis Lalli, Ryan Metz, Hallie Snyder Sacchetta
and Caitlin Hippeli, signing singly, the undersigned?s true and lawful
attorney-in-fact to:

(1) Execute for and on behalf of the undersigned, in the undersigned?s
capacity as an officer, director and/or shareholder of West Pharmaceutical
Services, Inc. (the ?Company?), Forms 3, 4, and 5 and amendments thereto
in accordance with Section 16(a) of the Securities Exchange Act of 1934 and
the rules thereunder;

(2) Do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4, or 5
or amendment thereto and timely file such form with the United States
Securities and Exchange Commission (the ?SEC?) and any stock exchange or
similar authority; and

(3)Take any other action of any type whatsoever, which, in the opinion of such
attorney-in-fact, may be necessary or desirable in connection with the
foregoing authority, it being understood that the documents executed by such
attorney-in-fact on behalf of the undersigned pursuant to this Power of
Attorney shall be in such form and shall contain such terms and conditions
as such attorney-in-fact may approve.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and
powers herein granted, as fully to all intents and purposes as the undersigned
might or could do if personally present, with full power of substitution or
revocation, hereby ratifying and confirming all that such attorney-in-fact,
or such attorney-in-fact?s substitute or substitutes, shall lawfully do or
cause to be done by virtue of this Power of Attorney and the rights and powers
herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving
in such capacity at the request of the undersigned, are not assuming, nor is
the Company assuming, any of the undersigned?s responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to
the undersigned?s holdings of and transaction in securities of the Company,
unless earlier revoked by the undersigned in a signed writing delivered to
the foregoing attorneys-in-fact.  This Power of Attorney may be filed with
the SEC as a confirming statement of the authority granted herein.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 4th day of August 2025.

SIGNATURE

/s/ Robert W. McMahon

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>McMahon Robert W.<br><sub>(Last) (First) (Middle)</sub><br>530 HERMAN O. WEST DRIVE<br><sub>(Street)</sub><br>EXTON, PA 19341<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-08-11 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_SVP & Chief Financial Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>WEST PHARMACEUTICAL SERVICES INC [ WST ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Rst. Stock Unit | $0 | 2025-08-11 |  | A |  | 12670 |  | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 12670 | $0 | 12670 | D |  |
| Rst. Stock Unit | $0 | 2025-08-11 |  | A |  | 3168 |  | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 3168 | $0 | 3168 | D |  |
| Stock Option (Right to Buy) | $240.33 | 2025-08-11 |  | A |  | 7647 |  | 2026-08-11<sup>(2)</sup> | 2035-08-11 | Common Stock | 7647 | $240.33 | 7647 | D |  |
| Stock Option (Right to Buy) | $240.33 | 2025-08-11 |  | A |  | 7137 |  | 2026-08-11<sup>(2)</sup> | 2035-08-11 | Common Stock | 7137 | $240.33 | 7137 | D |  |

---

### Footnotes:

(1) This award vests in three installments. 4,223 shares will vest six months from the grant date, 6,335 shares will vest 12 months from the grant date, and 2,112 shares will vest 24 months from the grant date.

(2) This award vests in four equal installments beginning on August 11, 2026.

**Signature:** /s/ Caitlin Hippeli, as an agent for Robert W. McMahon  
**Date:** 2025-08-12

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**